Replies to post #85817 on Biotech Values

[DewDiligence]

IDIX 2009-2010 News Flow

[Updated for PK/food trial of IDX899 (#msg-44790049).]


HCV

Any day: Start phase-1 trial of IDX375. (A CTA, the European equivalent of an IND, was submitted during 3Q09.)

Any day: Submit IND/CTA for IDX316. Start phase-1 trial in 1Q010.

Mid 2010: Report top-line phase-2 data for IDX184.

Timing uncertain (probably 1H10): Ink IDX184 partnership.

Nov 2010: Present complete phase-2 data for IDX184 at AASLD.

Timing uncertain: Submit IND/CTA for lead compound from NS5A program.


HIV

Mar 2010: GSK* completes IDX899 PK/food study testing multiple formulations at 100mg qD (#msg-44790049).

2Q10: Start phase-2b trial of IDX899 using the preferred 100mg formulation from the PK/food study.

*GSK is the operator of ViiV Healthcare, the joint venture with PFE that is the licensee of IDX899 (#msg-43254006).